Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

CDC advisers endorse booster shots that target omicron for Americans 12 and up

The United States should replace most of its COVID-19 booster shots with updated versions that target the dominant omicron strains, an influential group of vaccine experts that advises the Centers for Disease Control and Prevention said Thursday.

Los Angeles Times

CDC advisers back use of updated COVID-19 vaccine boosters - Roll Call

Moderna’s shot will be available to adults 18 and older, and Pfizer’s will be available to individuals 12 and older.

Roll Call

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

CDC recommends new booster shots to fight omicron

CDC Director Rochelle Walensky has signed off on updated versions of the Moderna and Pfizer-BioNTech vaccines that target the original virus and the omicron subvariants.

WEKU

Everyone in Their 30s Should Own These 2 Stocks

The stock market has been down following Fed Chair Jerome Powell’s Jackson Hole speech that signaled continued monetary policy tightening. We think in this current volatile backdrop, people planning their retirement savings in their 30s should invest in fundamentally sound dividend-paying stocks Pfizer (PFE) and Costco (COST). Read more….

StockNews.com

CDC advisers weigh who needs updated COVID booster and when

Government advisers are debating who should should get new updated COVID-19 boosters and when

The Independent UK

EU regulator approves Omicron vaccines

The European Union’s drug regulator has recommended the use of two Omicron-tailored vaccines developed by the Pfizer-BioNTech partnership and Moderna Inc ahead of a fresh booster programme this fall across the continent.

Bangkok Post

Read news from The Economist, FT, and more,
with one subscription

Will omicron-specific booster shots be more effective at combating COVID-19? 5 questions answered

On Sept. 1, 2022, the Centers for Disease Control and Prevention endorsed the use of updated COVID-19 booster shots that are specifically tailored to combat the two most prevalent omicron subvariants, BA.4 and BA.5. The decision comes just a day after the Food and Drug Administration’s emergency use authorization of…

The Conversation

New COVID-19 booster shots could be available in Chicago after Labor Day

The FDA today authorized the new booster, which could arrive as early as next week in Chicago, where nearly 2 million residents are expected to be eligible.

Chicago Sun-Times

What are the side effects of the new Covid-19 bivalent booster?

Last week, the FDA authorized both Pfizer and Moderna's Omicron-specific jabs. Experts say to get them as soon as they are available to you.

Inverse

FDA clears way for boosters targeted at latest COVID variants

COVID-19 boosters from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE that are tailored to the latest COVID-19 omicron variants got U.S. regulatory clearance, a move toward additional protection as concern grows about potential new waves in the fall and winter.

Tribune News Service

FDA authorizes first revamp of COVID vaccines to target omicron

The new shots from Moderna and Pfizer-BioNTech target both the original strain of the coronavirus and the omicron BA.4/BA.5 subvariants that most people are catching now.

WEKU

US clears updated Covid boosters targeting the newest Omicron strain

Omicron booster shots could become available within days

The Independent UK

US clears updated COVID boosters targeting newest variants

U.S. regulators have authorized updated COVID-19 boosters, the first to directly target today's most common omicron strain

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Roll Call

FDA greenlights new COVID-19 booster despite limited data - Roll Call

The Food and Drug Administration granted emergency authorization to Pfizer and Moderna for updated COVID-19 booster shots.

Benzinga

What Are Whales Doing With Pfizer

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The Canberra Times

COVID-19 vaccine now available for at-risk children under five as new cases remain low

Young children with complex health conditions are now eligible for COVID vaccinations.

Benzinga

This Is What Whales Are Betting On Pfizer

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 29 strange trades.

Get all your
news in one place.

100's of premium titles.
One news app.

Inverse

Should you get a Covid-19 booster now, or wait until the fall?

As we gear up for another wave of Covid-19 this fall, experts say you should definitely be prepared to get a booster shot. Here's when you should get it.

Axios

Moderna's COVID vaccine lawsuit looks ahead to future markets

Moderna's COVID vaccine lawsuit looks beyond the pandemic to future markets

Los Angeles Times

Omicron COVID-19 booster shots are coming: What you need to know

The next generation of COVID-19 booster shots — tailored specifically to combat the highly infectious family of omicron subvariants — could roll out early next month.

Tribune News Service

Q&A: The new COVID vaccine booster is coming. Should you get it?

The COVID-19 vaccine is getting an upgrade.

Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Asharq Al-Awsat

Moderna Sues Pfizer/BioNTech for Patent Infringement over COVID Vaccine

Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic. Pfizer shares fell nearly 1%, while BioNTech US-listed shares were down about 1.5%…

Tribune News Service

Biden team aims for omicron-targeted shots in arms by Labor Day

The Biden administration plans to begin offering next-generation COVID-19 booster shots as soon as the Labor Day weekend, according to people familiar with the matter, aiming to stave off a fall surge in cases of the disease.

1 … 40 41 42 43

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

351 stories

PFE

348 stories

Centers for Disease Control and Prevention

National Institutes of Health

84 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.